HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of 14 weeks of TNF alpha blockade treatment on lipid profile in ankylosing spondylitis.

AbstractOBJECTIVE:
Cardiovascular morbidity and mortality seem to be increased in ankylosing spondylitis, perhaps as the result of biological inflammation and consecutive dyslipidemia. This study aims to investigate the impact of TNF alpha-inhibitors, an effective treatment, on lipid profile.
METHODS:
Thirty-four ankylosing spondylitis (AS) patients with active disease undergoing anti-TNF alpha therapy (n=20, infliximab; n=7, etanercept; n=7, adalimumab) were recruited. Disease activity parameters, total cholesterol, LDL-cholesterol, HDL-cholesterol and triglycerides were assessed at baseline and after 14 weeks of treatment.
RESULTS:
After 14 weeks of TNF alpha blockade treatment, there was a significant increase in levels of total cholesterol (5.08+/-1.20 vs. 4.73+/-1.12 mmol/l; p=0.01) and HDL-cholesterol (1.61+/-0.47 vs. 1.47+/-0.35 mmol/l; p=0.008), but no resulting change in the atherogenic index (3.43+/-1.13 vs. 3.35+/-0.93; p=0.87). There was also no change in concentrations of triglycerides (1.33+/-1.22 vs. 1.27+/-0.98 mmol/l; p=0.794) and LDL-cholesterol (3.15+/-0.99 vs. 2.91+/-0.93 mmol/l; p=0.24). TNF alpha inhibitor treatment was followed by a significant improvement in all disease activity parameters: VAS pain or VAS disease activity, BASDAI or BASFI and systemic inflammation. Sub-group analysis showed that monoclonal antibodies increased total and LDL-cholesterol levels but did not change the atherogenic index. Conversely, 14 weeks of etanercept treatment was followed by no change in lipid profile.
CONCLUSION:
TNF alpha inhibitors may be successful in reducing cardiovascular risk in AS, as in RA, but not by affecting lipid profile. However, there is insufficient documented evidence, and long-term investigations are needed to define the possible protective mechanisms of TNFalpha inhibitor treatment in spondylarthropathies.
AuthorsSylvain Mathieu, Jean-Jacques Dubost, Anne Tournadre, Sandrine Malochet-Guinamand, Jean-Michel Ristori, Martin Soubrier
JournalJoint bone spine (Joint Bone Spine) Vol. 77 Issue 1 Pg. 50-2 (Jan 2010) ISSN: 1778-7254 [Electronic] France
PMID20022785 (Publication Type: Journal Article)
CopyrightCopyright 2009 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.
Chemical References
  • Antirheumatic Agents
  • Immunoglobulin G
  • Lipids
  • Receptors, Tumor Necrosis Factor
  • Triglycerides
  • Tumor Necrosis Factor-alpha
  • Cholesterol
  • Etanercept
Topics
  • Adult
  • Antirheumatic Agents (therapeutic use)
  • Cholesterol (blood)
  • Etanercept
  • Humans
  • Immunoglobulin G (therapeutic use)
  • Lipid Metabolism (drug effects, physiology)
  • Lipids (blood)
  • Male
  • Pain
  • Receptors, Tumor Necrosis Factor (therapeutic use)
  • Severity of Illness Index
  • Spondylitis, Ankylosing (blood, drug therapy, physiopathology)
  • Triglycerides (blood)
  • Tumor Necrosis Factor-alpha (antagonists & inhibitors, blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: